Pharma generics: Semaglutide patent expiry to open Rs 50-billion opportunity; Indian players eye FY27 boost

The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to create a revenue opportunity of more than Rs 50 billion for generic pharmaceutical companies over the next 12 to 15 months, according to an industry update by Systematix Institutional Research.The report said…

Read More

Buy, sell or hold: Stock recommendations for March 12, 2026 by brokers

Motilal Oswal Securities has initiated its coverage of Jio Financial Services with a buy recommendation and a target price of Rs 320. Analysts said the company is architecting India’s next-gen financial services platform, leveraging ecosystem synergies, data, distribution and discipline for scalable finance. While near-term profitability remains subdued due to the incubation phase of multiple…

Read More

US court enters $1 billion default judgment against Byju Raveendran

File photo: Byju Raveendran (Picture credit: IANS) BENGALURU: The Delaware Bankruptcy Court has entered a default judgment of more than $1.07 billion against Byju Raveendran, after finding that the edtech founder repeatedly failed to comply with court-ordered discovery in the Byju’s Alpha adversary proceeding. A default judgment is a ruling issued when a party does…

Read More

Gold & silver outlook: Bullion seen holding firm next week; US tariff verdict, geopolitics in focus

Gold and silver prices are expected to remain firm next week as traders brace for heightened geopolitical risks and uncertainty around the US Supreme Court’s impending verdict on President Donald Trump’s tariff policy, analysts said.Market participants will also track inflation data from major economies including the US, India and Germany, alongside trade and investment numbers…

Read More